Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies

Anaphore's novel Atrimer platform creates trivalent protein drugs to bind all three domains on trivalent ligands and receptors, a presumed advantage over two-armed antibodies.